“The
Report Prostate Cancer - 5EU Drug Forecast and Market Analysis to
2023 provides information on pricing, market analysis, shares,
forecast, and company profiles for key industry participants. -
MarketResearchReports.biz"
Prostate
cancer
is the second most common cancer in men worldwide, after skin cancer.
It accounts for 15% of all the cancers diagnosed in men, and thus
represents a huge burden on healthcare systems. While patients
diagnosed with early-stage, localized prostate cancer can be cured,
patients who are diagnosed with or progress to castration-resistant
prostate cancer (CRPC) have no curative options. This report focuses
on the current treatment landscape, unmet needs, pipeline assessment
and market outlook for prostate cancer. . Since 2010, five new drugs
have been approved for the treatment of CRPC: Dendreons Provenge,
Sanofis Jevtana, Johnson & Johnsons Zytiga, Medivation/Astellas
Xtandi, and Bayers Xofigo. During the forecast period from 2013-2023,
GlobalData expects that nine new late-stage pipeline agents will
launch, eight of which will be for the treatment of CRPC. As a result
of this unprecedented level of clinical development, GlobalData
predicts there will be massive changes in the CRPC treatment
paradigm. In addition, due to the influx of new therapies, the size
of the prostate cancer market across the nine major pharmaceutical
markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, Brazil,
and Canada) will increase three-fold.
The
5EU is the second largest market for prostate cancer, after the US.
This strong growth will be a result of the increasing incidence of
prostate cancer as the population ages, increased sales resulting
from the launch of eight new premium-priced pipeline products during
the forecast period, and the label extension of Xtandi into the
nmCRPC and hormone-sensitive prostate cancer patient populations.
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/841025
Scope
-
Overview of Prostate Cancer including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as an
overview on the competitive landscape.
-
Detailed information on the key drugs in 5EU including product
description, safety and efficacy profiles as well as a SWOT analysis.
-
Sales forecast for the top drugs in 5EU from 2013-2023.
-
Analysis of the impact of key events as well the drivers and
restraints affecting 5EU Prostate Cancer market.
Reasons
to buy
-
Understand and capitalize by identifying products that are most
likely to ensure a robust return
-
Stay ahead of the competition by understanding the changing
competitive landscape for Prostate Cancer.
-
Effectively plan your M&A and partnership strategies by
identifying drugs with the most promising sales potential
-
Make more informed business decisions from insightful and in-depth
analysis of drug performance
-
Obtain sales forecast for drugs from 2013-2023 in 5EU.
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
Table
of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 9
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 11
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and
Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 13
3.2 Staging 14
3.3 Symptoms 18
3.4 Prognosis 18
3.5 Quality of Life 19
4 Disease Management 20
4.1 Diagnosis and Treatment
Overview 20
4.1.1 Screening and Diagnosis
20
4.1.2 Treatment Guidelines and
the Leading Prescribed Drugs 22
4.1.3 Clinical Practice 24
4.2 France 34
4.3 Germany 35
4.4 Italy 36
4.5 Spain 37
4.6 UK 38
5 Competitive Assessment 39
5.1 Overview 39
5.2 Product Profiles - Major
Brands, Targeted Therapies 40
5.2.1 Zytiga (abiraterone
acetate) 40
5.2.2 Xtandi (enzalutamide) 46
5.2.3 Xofigo (radium 223
dichloride) 51
5.3 Product Profiles - Major
Brands, Chemotherapies 57
5.3.1 Jevtana (cabazitaxel) 57
5.4 Product Profiles - Major
Brands, Therapeutic Vaccines 61
5.4.1 Provenge (sipuleucel-T)
61
5.5 Product Profiles - Major
Brands, Hormone Therapies 65
5.5.1 Zoladex (goserelin
acetate) 65
5.5.2 Lupron Depot (leuprolide
acetate) 68
5.5.3 Eligard (leuprolide
acetate) 71
5.5.4 Trelstar (triptorelin
acetate) 73
5.5.5 Firmagon (degarelix) 75
5.5.6 Casodex (bicalutamide) 78
5.6 Product Profiles - Major
Brands, Bone Therapies 81
5.6.1 Zometa (zoledronic acid)
81
5.6.2 Xgeva (denosumab) 83
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment